ATLAS Molecular Pharma succeeded with the competitive NEOTEC call (CDTI), obtaining a grant for a total amount of 213.000 EUR during the period 2017-2018. The NEOTEC Program aims to support the creation and consolidation of technology-based companies and it takes into account the creation of new technology and the innovation character of the business initiative.
ATLAS Molecular Pharma has been awarded with one of the prestigious NEOTEC grants (2016 call)
Para compartir esta historia, elija cualquier plataforma
Related Posts
-
Atlas Molecular Pharma recibe la aprobación de la Administración de Drogas y Alimentos de los Estados Unidos de un medicamento huérfano para el tratamiento de la porfiria eritropoyética congénita Gallery
Atlas Molecular Pharma recibe la aprobación de la Administración de Drogas y Alimentos de los Estados Unidos de un medicamento huérfano para el tratamiento de la porfiria eritropoyética congénita
-
Atlas Molecular Pharma receives approval by the US Food & Drug Administration of an Orphan Drug for the treatment of Congenital Erythropoietic Porphyria Gallery
Atlas Molecular Pharma receives approval by the US Food & Drug Administration of an Orphan Drug for the treatment of Congenital Erythropoietic Porphyria
-
ATLAS Molecular Pharma awarded with the research grant ‘Cristina Pericàs Almendro’ 2018-2019 by the Spanish Association for Creutzfeldt-Jakob disease Gallery
ATLAS Molecular Pharma awarded with the research grant ‘Cristina Pericàs Almendro’ 2018-2019 by the Spanish Association for Creutzfeldt-Jakob disease
-
Atlas Molecular Pharma recibe la aprobación de la Comisión Europea de un medicamento huérfano para el tratamiento de la Porfiria Eritropoyética Congénita Gallery
Atlas Molecular Pharma recibe la aprobación de la Comisión Europea de un medicamento huérfano para el tratamiento de la Porfiria Eritropoyética Congénita
-
Atlas Molecular Pharma receives approval by the European Commission of an Orphan Medicinal Product for the treatment of Congenital Erythropoietic Porphyria Gallery
Atlas Molecular Pharma receives approval by the European Commission of an Orphan Medicinal Product for the treatment of Congenital Erythropoietic Porphyria